Literature DB >> 2410329

Elevation of serum CA 125 prior to diagnosis of an epithelial ovarian carcinoma.

R C Bast, F P Siegal, C Runowicz, T L Klug, V R Zurawski, D Schonholz, C J Cohen, R C Knapp.   

Abstract

In a single fortuitous case it has been possible to measure serum levels of CA 125 during 3 years preceding the diagnosis of an epithelial ovarian carcinoma. CA 125 levels were elevated 10-12 months prior to clinical detection of the malignancy. CA 125 deserves further evaluation as a marker for early detection of ovarian cancer.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 2410329     DOI： 10.1016/0090-8258(85)90015-0

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN： 0090-8258            Impact factor:   5.482


  12 in total

1.  Early detection of ovarian cancer.

Authors:  Partha M Das; Robert C Bast
Journal:  Biomark Med       Date:  2008-06       Impact factor: 2.851

Review 2.  Early detection of ovarian cancer: new technologies in pursuit of a disease that is neither common nor rare.

Authors:  Robert C Bast
Journal:  Trans Am Clin Climatol Assoc       Date:  2004

Review 3.  Molecular approaches to personalizing management of ovarian cancer.

Authors:  R C Bast
Journal:  Ann Oncol       Date:  2011-12       Impact factor: 32.976

Review 4.  The structural relationship of blood group-related oligosaccharides in human carcinoma to biological function: a perspective.

Authors:  V E Dube
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

5.  Proteomic biomarkers in combination with CA 125 for detection of epithelial ovarian cancer using prediagnostic serum samples from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.

Authors:  Lee E Moore; Ruth M Pfeiffer; Zhen Zhang; Karen H Lu; Eric T Fung; Robert C Bast
Journal:  Cancer       Date:  2011-06-29       Impact factor: 6.860

Review 6.  Ovarian cancer immunotherapy: opportunities, progresses and challenges.

Authors:  Bei Liu; John Nash; Carolyn Runowicz; Helen Swede; Richard Stevens; Zihai Li
Journal:  J Hematol Oncol       Date:  2010-02-10       Impact factor: 17.388

7.  Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer.

Authors:  Zhen Zhang; Yinhua Yu; Fengji Xu; Andrew Berchuck; Carolien van Haaften-Day; Laura J Havrilesky; Henk W A de Bruijn; Ate G J van der Zee; Robert P Woolas; Ian J Jacobs; Steven Skates; Daniel W Chan; Robert C Bast
Journal:  Gynecol Oncol       Date:  2007-10-24       Impact factor: 5.482

Review 8.  Ovarian cancer biomarkers: current options and future promise.

Authors:  Christine M Coticchia; Jiang Yang; Marsha A Moses
Journal:  J Natl Compr Canc Netw       Date:  2008-09       Impact factor: 11.908

9.  Serum S100A6 concentration predicts peritoneal tumor burden in mice with epithelial ovarian cancer and is associated with advanced stage in patients.

Authors:  Bih-Rong Wei; Shelley B Hoover; Mark M Ross; Weidong Zhou; Francesco Meani; Jennifer B Edwards; Elizabeth I Spehalski; John I Risinger; W Gregory Alvord; Octavio A Quiñones; Claudio Belluco; Luca Martella; Elio Campagnutta; Antonella Ravaggi; Ren-Ming Dai; Paul K Goldsmith; Kevin D Woolard; Sergio Pecorelli; Lance A Liotta; Emanuel F Petricoin; R Mark Simpson
Journal:  PLoS One       Date:  2009-10-30       Impact factor: 3.240

10.  Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study.

Authors:  Garnet L Anderson; Martin McIntosh; Lieling Wu; Matt Barnett; Gary Goodman; Jason D Thorpe; Lindsay Bergan; Mark D Thornquist; Nathalie Scholler; Nam Kim; Kathy O'Briant; Charles Drescher; Nicole Urban
Journal:  J Natl Cancer Inst       Date:  2009-12-30       Impact factor: 13.506
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.